{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:30:40Z","timestamp":1794137440012,"version":"4.8.0"},"reference-count":253,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.omtn.2024.102195","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T01:44:54Z","timestamp":1713923094000},"page":"102195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges"],"prefix":"10.1016","volume":"35","author":[{"given":"Wanjun","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3691-478X","authenticated-orcid":false,"given":"Leo Tsz On","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102195_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature14663","article-title":"Universal allosteric mechanism for Galpha activation by GPCRs","volume":"524","author":"Flock","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2024.102195_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1124\/pr.57.2.5","article-title":"International union of pharmacology. XLVI. G protein-coupled receptor list","volume":"57","author":"Foord","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.omtn.2024.102195_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-00435-w","article-title":"G protein-coupled receptors: structure- and function-based drug discovery","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib4","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3389\/fphys.2018.01673","article-title":"Olfactory, taste, and photo sensory receptors in non-sensory organs: it just makes sense","volume":"9","author":"Dalesio","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.omtn.2024.102195_bib5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1124\/pr.110.003350","article-title":"The significance of G protein-coupled receptor crystallography for drug discovery","volume":"63","author":"Salon","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.omtn.2024.102195_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e05007","article-title":"Nucleic acid-based therapy for coronavirus disease 2019","volume":"6","author":"Piyush","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.omtn.2024.102195_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s12276-022-00757-5","article-title":"RNA therapy: rich history, various applications and unlimited future prospects","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.omtn.2024.102195_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104550","article-title":"RNA-based therapeutics for colorectal cancer: Updates and future directions","volume":"152","author":"Liu","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.omtn.2024.102195_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12943-023-01807-w","article-title":"The use of RNA-based treatments in the field of cancer immunotherapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2024.102195_bib11","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41574-020-00459-w","article-title":"Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges","volume":"17","author":"Ghislain","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.omtn.2024.102195_bib13","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.ddmod.2012.03.001","article-title":"Conducting the G-protein coupled receptor (GPCR) signaling symphony in cardiovascular diseases: new therapeutic approaches","volume":"9","author":"Belmonte","year":"2012","journal-title":"Drug Discov. Today. Dis. Models"},{"key":"10.1016\/j.omtn.2024.102195_bib14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/imr.12752","article-title":"Concepts of GPCR-controlled navigation in the immune system","volume":"289","author":"L\u00e4mmermann","year":"2019","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omtn.2024.102195_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110802","article-title":"Hijacking of GPCRs and RTKs by pathogens","volume":"109","author":"Ayoub","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.omtn.2024.102195_bib16","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.3390\/cells10123288","article-title":"An insight into GPCR and G-proteins as cancer drivers","volume":"10","author":"Chaudhary","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2024.102195_bib17","article-title":"Role of GPCR signaling and calcium dysregulation in Alzheimer's disease","volume":"101","author":"Mondal","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.omtn.2024.102195_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.768156","article-title":"Role of G protein-coupled receptors in microglial activation: implication in parkinson's disease","volume":"13","author":"Gu","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.omtn.2024.102195_bib19","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.biotechadv.2013.08.017","article-title":"An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases","volume":"31","author":"Heng","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.omtn.2024.102195_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.785703","article-title":"Innovative therapeutic approaches for huntington's disease: from nucleic acids to GPCR-targeting small molecules","volume":"15","author":"Komatsu","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.omtn.2024.102195_bib21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","article-title":"Impact of GPCR structures on drug discovery","volume":"181","author":"Congreve","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.omtn.2024.102195_bib22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tips.2007.06.003","article-title":"Conformational complexity of G-protein-coupled receptors","volume":"28","author":"Kobilka","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib23","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: new agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib25","series-title":"Global G-Protein Coupled Receptors (GPCRs) Market Report to 2027 - Developments in Structural Biology and Receptor Pharmacology Offer Novel Opportunities","author":"Markets","year":"2022"},{"key":"10.1016\/j.omtn.2024.102195_bib26","series-title":"Global G-protein coupled receptors (GPCRs) industry","first-page":"359","year":"2022"},{"key":"10.1016\/j.omtn.2024.102195_bib27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrd.2018.180","article-title":"GPCR drug discovery: Integrating solution NMR data with crystal and cryo-EM structures","volume":"18","author":"Shimada","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.omtn.2024.102195_bib29","first-page":"S21","article-title":"The consice guide to pharmacology 2019\/20: G protein-coupled receptors","volume":"176","author":"Alexander","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s42000-018-0009-5","article-title":"Current understanding of the structure and function of family B GPCRs to design novel drugs","volume":"17","author":"Karageorgos","year":"2018","journal-title":"Hormones (Basel)"},{"key":"10.1016\/j.omtn.2024.102195_bib31","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41573-020-0062-z","article-title":"Advances in therapeutic peptides targeting G protein-coupled receptors","volume":"19","author":"Davenport","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omtn.2024.102195_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.clinthera.2005.06.015","article-title":"Acamprosate for the treatment of alcohol dependence","volume":"27","author":"Boothby","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.omtn.2024.102195_bib35","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.2147\/CMAR.S195723","article-title":"Profile of glasdegib for the treatment of newly diagnosed acute myeloid leukemia (AML): evidence to date","volume":"14","author":"Iyer","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.omtn.2024.102195_bib36","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signalling: from simple switches to allosteric microprocessors","volume":"17","author":"Smith","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: An emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.omtn.2024.102195_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/sja.sja_510_21","article-title":"Oliceridine- opioid of the 21(st) century","volume":"16","author":"Goudra","year":"2022","journal-title":"Saudi J. Anaesth."},{"key":"10.1016\/j.omtn.2024.102195_bib39","first-page":"6","article-title":"Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia","volume":"597","author":"Christopher","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2024.102195_bib40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1476-5381.2009.00169.x","article-title":"G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function","volume":"158","author":"Milligan","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines6020065","article-title":"Utilizing peptide ligand GPCRs to image and treat pancreatic cancer","volume":"6","author":"Matters","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2024.102195_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fmed.2019.00009","article-title":"Discovery of pathologic GPCR aggregation","volume":"6","author":"Quitterer","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.omtn.2024.102195_bib43","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1096\/fj.13-246868","article-title":"Transmembrane peptides as unique tools to demonstrate the in\u00a0vivo action of a cross-class GPCR heterocomplex","volume":"28","author":"Lee","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.omtn.2024.102195_bib44","doi-asserted-by":"crossref","first-page":"6937","DOI":"10.1021\/acs.jmedchem.1c00484","article-title":"Orally active peptide vector allows using cannabis to fight pain while avoiding side effects","volume":"64","author":"Gallo","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.omtn.2024.102195_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27010210","article-title":"The structural basis of peptide binding at Class A G protein-coupled receptors","volume":"27","author":"Vu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2024.102195_bib46","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib47","doi-asserted-by":"crossref","first-page":"e525","DOI":"10.1097\/CCM.0000000000000300","article-title":"The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis","volume":"42","author":"Maybauer","year":"2014","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.omtn.2024.102195_bib48","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.omtn.2024.102195_bib49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrd.2017.173","article-title":"Opportunities for therapeutic antibodies directed at G-protein-coupled receptors","volume":"16","author":"Hutchings","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib50","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4103\/joacp.JOACP_3_19","article-title":"Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention","volume":"36","author":"Garg","year":"2020","journal-title":"J.\u00a0Anaesthesiol. Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib51","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2147\/OTT.S165615","article-title":"Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma","volume":"12","author":"Ollila","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia"},{"key":"10.1016\/j.omtn.2024.102195_bib53","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2022.5302","article-title":"Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)","volume":"60","author":"Lu","year":"2022","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.omtn.2024.102195_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib55","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mce.2019.03.003","article-title":"GPCR photopharmacology","volume":"488","author":"Ricart-Ortega","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.omtn.2024.102195_bib56","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2018.05.033","article-title":"Remote control of movement disorders using a photoactive adenosine A2A receptor antagonist","volume":"283","author":"Taura","year":"2018","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtn.2024.102195_bib57","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/nat.2012.0350","article-title":"Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology","volume":"22","author":"Guo","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib58","doi-asserted-by":"crossref","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","article-title":"The progress and promise of RNA medicine horizontal line an arsenal of targeted treatments","volume":"65","author":"Sasso","year":"2022","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.omtn.2024.102195_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052736","article-title":"Current advances in RNA therapeutics for human diseases","volume":"23","author":"Zogg","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of rous sarcomavirus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.omtn.2024.102195_bib61","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J.\u00a0Clin. Med."},{"key":"10.1016\/j.omtn.2024.102195_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102195_bib63","first-page":"16","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","year":"2016","journal-title":"Postdoc J."},{"key":"10.1016\/j.omtn.2024.102195_bib64","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1073\/pnas.0406700102","article-title":"Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102195_bib65","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1093\/nar\/gku184","article-title":"Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides","volume":"42","author":"Ward","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102195_bib66","unstructured":"Holgersen, E, Gandhi, S, Zhou, Y, Kim, J, Vaz, B, Bogojeski, J, Bugno, M, Shalev, Z, Cheung-Ong, K, Gon\u00e7alves, J, et\u00a0al. (2020)."},{"key":"10.1016\/j.omtn.2024.102195_bib67","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: An overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.omtn.2024.102195_bib68","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.ymthe.2017.06.002","article-title":"RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus","volume":"25","author":"Liang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib69","first-page":"14","article-title":"Fomivirsen approved for CMV retinitis","volume":"4","author":"Roehr","year":"1998","journal-title":"J.\u00a0Int. Assoc. Physicians AIDS Care"},{"key":"10.1016\/j.omtn.2024.102195_bib70","series-title":"Gapmers: Methods and Protocols","first-page":"3","article-title":"Invention and early history of gapmers","author":"Lim","year":"2020"},{"key":"10.1016\/j.omtn.2024.102195_bib71","first-page":"651","article-title":"Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia","volume":"8","author":"Bell","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.omtn.2024.102195_bib72","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/pr.120.019554","article-title":"RNA drugs and RNA targets for small molecules: principles, progress, and challenges","volume":"72","author":"Yu","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.omtn.2024.102195_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib74","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3349\/ymj.2020.61.4.273","article-title":"Nusinersen as a therapeutic agent for spinal muscular atrophy","volume":"61","author":"Li","year":"2020","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.omtn.2024.102195_bib75","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1038\/mt.2016.188","article-title":"Eteplirsen approved for duchenne muscular dystrophy: The FDA faces a difficult choice","volume":"24","author":"Stein","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib76","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-020-01106-1","article-title":"The administration of antisense oligonucleotide golodirsen reduces pathological regeneration in patients with Duchenne muscular dystrophy","volume":"9","author":"Scaglioni","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.omtn.2024.102195_bib77","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102195_bib78","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102195_bib79","series-title":"FDA Approves Treatment of Amyotrophic Lateral Sclerosis Associated with a Mutation in the SOD1 Gene","year":"2023"},{"key":"10.1016\/j.omtn.2024.102195_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev-pharmtox-010716-104558","article-title":"Aptamers as therapeutics","volume":"57","author":"Nimjee","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.omtn.2024.102195_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24193598","article-title":"Inside the black Box: what makes SELEX better?","volume":"24","author":"Komarova","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2024.102195_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18102142","article-title":"Recent advances in SELEX technology and aptamer applications in biomedicine","volume":"18","author":"Zhuo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib83","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.7150\/thno.25958","article-title":"Aptamers in the therapeutics and diagnostics pipelines","volume":"8","author":"Kaur","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2024.102195_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122561","article-title":"Aptamers as smart ligands for targeted drug delivery in cancer therapy","volume":"14","author":"Wei","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib85","first-page":"6","article-title":"Pegaptanib in the treatment of wet, age-related macular degeneration","volume":"I","author":"Vinores","year":"2006","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.omtn.2024.102195_bib86","first-page":"10","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Eugene","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/bloodadvances.2021005410","article-title":"Defibrotide: real-world management of veno-occlusive disease\/sinusoidal obstructive syndrome after stem cell transplant","volume":"6","author":"Nauffal","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omtn.2024.102195_bib88","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14728222.2021.1944101","article-title":"Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes","volume":"25","author":"Richardson","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.omtn.2024.102195_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010086","article-title":"CXCL12 in pancreatic cancer: its function and potential as a therapeutic drug target","volume":"14","author":"Malik","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omtn.2024.102195_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071810","article-title":"Colorectal cancer: the contribution of CXCL12 and its receptors CXCR4 and CXCR7","volume":"14","author":"Go\u00efta","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omtn.2024.102195_bib91","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.V122.21.1951.1951","article-title":"Anti-CXCL12\/SDF-1 Spiegelmer\u00ae Nox-A12 alone and In combination with Bortezomib and dexamethasone In patients with relapsed multiple myeloma: results from A Phase IIa study","volume":"122","author":"Ludwig","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2024.102195_bib92","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/bjophthalmol-2020-318452","article-title":"Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions","volume":"106","author":"Cabral De Guimaraes","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.omtn.2024.102195_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib94","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/lipd.12282","article-title":"S1P lyase siRNA dampens malignancy of DLD-1 colorectal cancer cells","volume":"56","author":"Faqar-Uz-Zaman","year":"2021","journal-title":"Lipids"},{"key":"10.1016\/j.omtn.2024.102195_bib95","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.2147\/OTT.S246632","article-title":"RSF-1 siRNA enhances tumor radiosensitivity in cervical cancer via enhanced DNA damage, cell cycle redistribution, and promotion of apoptosis","volume":"13","author":"Tian","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib96","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081586","article-title":"Nanoparticles-based strategies to improve the delivery of therapeutic small interfering RNA in precision oncology","volume":"14","author":"Huang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib97","doi-asserted-by":"crossref","first-page":"eabc7031","DOI":"10.1126\/sciadv.abc7031","article-title":"Blood-brain barrier\u2013penetrating siRNA nanomedicine for Alzheimer\u2019s disease therapy","volume":"6","author":"Zhou","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2024.102195_bib98","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcph.1480","article-title":"Patisiran pharmacokinetics, pharmacodynamics, and exposure-response analyses in the Phase 3 APOLLO trial in patients with hereditary transthyretin-mediated (hATTR) amyloidosis","volume":"60","author":"Zhang","year":"2020","journal-title":"J.\u00a0Clin. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib99","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.2147\/DDDT.S281631","article-title":"Spotlight on givosiran as a treatment option for adults with acute hepatic porphyria: design, development, and place in therapy","volume":"16","author":"Majeed","year":"2022","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/IJNRD.S293682","article-title":"Lumasiran in the management of patients with primary hyperoxaluria type 1: from bench to bedside","volume":"15","author":"D'ambrosio","year":"2022","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"10.1016\/j.omtn.2024.102195_bib101","first-page":"569","article-title":"Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts' opinion. The compromise between EBM and possibilities in healthcare","volume":"18","author":"Banach","year":"2022","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib102","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: First approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102195_bib103","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.omtn.2024.102195_bib104","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/15476286.2022.2052641","article-title":"Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications","volume":"19","author":"Gangopadhyay","year":"2022","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib106","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib107","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib108","doi-asserted-by":"crossref","first-page":"17337","DOI":"10.1073\/pnas.0607015103","article-title":"Small dsRNAs induce transcriptional activation in human cells","volume":"103","author":"Li","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102195_bib109","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/wrna.90","article-title":"Small RNA and transcriptional upregulation","volume":"2","author":"Portnoy","year":"2011","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"10.1016\/j.omtn.2024.102195_bib110","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/mtna.2012.20","article-title":"Gene expression profile changes after short-activating RNA-mediated induction of endogenous pluripotency factors in human mesenchymal stem cells","volume":"1","author":"Voutila","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102195_bib111","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26216530","article-title":"RNA activation-A novel approach to therapeutically upregulate gene transcription","volume":"26","author":"Tan","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2024.102195_bib112","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/1087057116637562","article-title":"Small-activating RNA can change nucleosome positioning in human fibroblasts","volume":"21","author":"Wang","year":"2016","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.omtn.2024.102195_bib113","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.ymthe.2017.07.018","article-title":"Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer","volume":"25","author":"Voutila","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4161\/epi.26942","article-title":"RNA-mediated gene activation","volume":"9","author":"Jiao","year":"2014","journal-title":"Epigenetics"},{"key":"10.1016\/j.omtn.2024.102195_bib115","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib116","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-20-0414","article-title":"MTL-CEBPA, a small activating RNA therapeutic upregulating C\/EBP-alpha, in patients with advanced liver cancer: A first-in-human, multicenter, open-label, Phase I trial","volume":"26","author":"Sarker","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2024.102195_bib117","series-title":"First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer","author":"Therapeutics","year":"2022"},{"key":"10.1016\/j.omtn.2024.102195_bib118","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3389\/fimmu.2020.00615","article-title":"Research advances in how the cGAS-STING pathway controls the cellular inflammatory response","volume":"11","author":"Wan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102195_bib119","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1016\/j.annonc.2022.07.605","article-title":"477P MTL-STING increases STING expression and potentiates efficacy of checkpoint inhibitor in murine preclinical model","volume":"33","author":"Tan","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.omtn.2024.102195_bib120","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of microRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'brien","year":"2018","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.omtn.2024.102195_bib121","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib122","first-page":"120","article-title":"The role of exportin-5 in microRNA biogenesis and cancer","volume":"16","author":"Wu","year":"2018","journal-title":"Dev. Reprod. Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib123","article-title":"A structural view of miRNA biogenesis and function","volume":"8","author":"Leit\u00e3o","year":"2022","journal-title":"Noncoding. RNA"},{"key":"10.1016\/j.omtn.2024.102195_bib124","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-021-01338-2","article-title":"RNA-based therapies: A cog in the wheel of lung cancer defense","volume":"20","author":"Khan","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2024.102195_bib125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41580-018-0059-1","article-title":"Regulation of microRNA biogenesis and its crosstalk with other cellular pathways","volume":"20","author":"Treiber","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib126","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1053\/j.gastro.2020.12.062","article-title":"miR-10b-5p rescues diabetes and gastrointestinal dysmotility","volume":"160","author":"Singh","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.omtn.2024.102195_bib127","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3389\/fimmu.2018.01377","article-title":"Anti-inflammatory microRNAs and their potential for inflammatory diseases treatment","volume":"9","author":"Tahamtan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102195_bib128","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102195_bib129","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2147\/DDDT.S288859","article-title":"The risks of miRNA therapeutics: In a drug target perspective","volume":"15","author":"Zhang","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib130","first-page":"7","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Glen","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.omtn.2024.102195_bib131","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and clinical advances of GalNAc-decorated nucleic acid therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102195_bib132","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/wrr.12660","article-title":"A synthetic microRNA-92a inhibitor (MRG-110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds","volume":"26","author":"Gallant-Behm","year":"2018","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.omtn.2024.102195_bib133","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehaa791","article-title":"CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure","volume":"42","author":"Batkai","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.omtn.2024.102195_bib134","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jid.2018.11.007","article-title":"A MicroRNA-29 mimic (Remlarsen) represses extracellular matrix expression and fibroplasia in the skin","volume":"139","author":"Gallant-Behm","year":"2019","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.omtn.2024.102195_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.710738","article-title":"RNA therapeutics - research and clinical advancements","volume":"8","author":"Feng","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.omtn.2024.102195_bib136","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib137","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2024.102195_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010166","article-title":"mRNA in the context of protein replacement therapy","volume":"15","author":"Vavilis","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib140","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12967-019-1804-8","article-title":"How mRNA therapeutics are entering the monoclonal antibody field","volume":"17","author":"Van Hoecke","year":"2019","journal-title":"J.\u00a0Transl. Med."},{"key":"10.1016\/j.omtn.2024.102195_bib141","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7150\/jca.63991","article-title":"Intravenous delivery of RNA encoding anti-PD-1 human monoclonal antibody for treating intestinal cancer","volume":"13","author":"Wu","year":"2022","journal-title":"J.\u00a0Cancer"},{"key":"10.1016\/j.omtn.2024.102195_bib142","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib143","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.omtn.2024.102195_bib144","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2024.102195_bib145","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","article-title":"Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: Design of a Phase 2a clinical trial","volume":"18","author":"Anttila","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2024.102195_bib146","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3390\/cells11121868","article-title":"One size does not fit all: the past, present and future of cystic fibrosis causal therapies","volume":"11","author":"Ensinck","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2024.102195_bib147","article-title":"mRNA-based cancer vaccines: A therapeutic strategy for the treatment of melanoma patients","volume":"9","author":"Bidram","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.omtn.2024.102195_bib148","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nbt.3784","article-title":"Oligonucleotide therapies for disorders of the nervous system","volume":"35","author":"Khorkova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102195_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030303","article-title":"Oligonucleotide-based therapies for renal diseases","volume":"9","author":"Cart\u00f3n-Garc\u00eda","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2024.102195_bib150","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib151","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3389\/fimmu.2017.01513","article-title":"Introducing membrane charge and membrane potential to T Cell signaling","volume":"8","author":"Ma","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102195_bib152","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.bioconjchem.8b00778","article-title":"Overcoming endosomal entrapment in drug delivery","volume":"30","author":"Pei","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2024.102195_bib153","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O'brien","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib154","doi-asserted-by":"crossref","DOI":"10.3390\/genes10020092","article-title":"RNA modifications modulate activation of Innate Toll-like receptors","volume":"10","author":"Freund","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.omtn.2024.102195_bib155","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1021\/acs.accounts.1c00521","article-title":"Immunogenicity of in\u00a0vitro-transcribed RNA","volume":"54","author":"Mu","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.omtn.2024.102195_bib156","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s11658-019-0196-3","article-title":"Editorial focus: understanding off-target effects as the key to successful RNAi therapy","volume":"24","author":"Bartoszewski","year":"2019","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.omtn.2024.102195_bib157","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1261\/rna.28106","article-title":"Off-target effects by siRNA can induce toxic phenotype","volume":"12","author":"Fedorov","year":"2006","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2024.102195_bib158","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","article-title":"Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides","volume":"87","author":"Geary","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2024.102195_bib159","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/cts.12624","article-title":"Targeting RNA: A transformative therapeutic strategy","volume":"12","author":"Yin","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25204659","article-title":"Modified nucleic acids: Expanding the capabilities of functional oligonucleotides","volume":"25","author":"Ochoa","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2024.102195_bib161","doi-asserted-by":"crossref","first-page":"13993","DOI":"10.1021\/acsnano.1c05099","article-title":"Delivery of oligonucleotide therapeutics: chemical modifications, lipid nanoparticles, and extracellular vesicles","volume":"15","author":"Bost","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2024.102195_bib162","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/nar\/gkn958","article-title":"RNA major groove modifications improve siRNA stability and biological activity","volume":"37","author":"Terrazas","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102195_bib163","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3762\/bjoc.17.76","article-title":"Beyond ribose and phosphate: selected nucleic acid modifications for structure-function investigations and therapeutic applications","volume":"17","author":"Liczner","year":"2021","journal-title":"Beilstein J. Org. Chem."},{"key":"10.1016\/j.omtn.2024.102195_bib164","article-title":"Recent advances in RNA therapeutics and RNA delivery systems based on nanoparticles","volume":"1","author":"Shin","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/ph15080909","article-title":"The medicinal chemistry of artificial nucleic acids and therapeutic oligonucleotides","volume":"15","author":"Bege","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.omtn.2024.102195_bib166","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2024.102195_bib167","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2024.102195_bib168","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1093\/nar\/gkaa670","article-title":"Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates","volume":"48","author":"Brown","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2024.102195_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050583","article-title":"Peptide-based nanoparticles for therapeutic nucleic acid delivery","volume":"9","author":"Boisgu\u00e9rin","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2024.102195_bib170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072006","article-title":"Application of nanoparticles for targeting G protein-coupled receptors","volume":"19","author":"Ma","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib171","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/btm2.10014","article-title":"ROS-responsive drug delivery systems","volume":"1","author":"Liang","year":"2016","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.omtn.2024.102195_bib172","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.7150\/thno.14858","article-title":"The smart drug delivery system and its clinical potential","volume":"6","author":"Liu","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2024.102195_bib173","article-title":"Advanced application of stimuli-responsive drug delivery system for inflammatory arthritis treatment","volume":"14","author":"Zhang","year":"2022","journal-title":"Mater. Today. Bio"},{"key":"10.1016\/j.omtn.2024.102195_bib174","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtn.2024.102195_bib175","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.omtn.2024.102195_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101675","article-title":"Lipid nanoparticles for organ-specific mRNA therapeutic delivery","volume":"13","author":"\u017bak","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib177","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtn.2024.102195_bib178","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2024.102195_bib179","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1021\/jacs.8b08976","article-title":"Nanoparticles that deliver RNA to bone marrow identified by in\u00a0vivo directed evolution","volume":"140","author":"Sago","year":"2018","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.omtn.2024.102195_bib180","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1039\/D1NA00712B","article-title":"Predictive high-throughput screening of PEGylated lipids in oligonucleotide-loaded lipid nanoparticles for neuronal gene silencing","volume":"4","author":"Sarode","year":"2022","journal-title":"Nanoscale Adv."},{"key":"10.1016\/j.omtn.2024.102195_bib181","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.apsb.2017.12.002","article-title":"Biomimetic nanoparticles for inflammation targeting","volume":"8","author":"Jin","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.omtn.2024.102195_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118859","article-title":"Advancement of nanoscience in development of conjugated drugs for enhanced disease prevention","volume":"268","author":"Taneja","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib183","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/bit.28205","article-title":"Ligand conjugated lipid-based nanocarriers for cancer theranostics","volume":"119","author":"Kumar","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omtn.2024.102195_bib184","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102195_bib185","article-title":"Genetically engineered liposome-like nanovesicles as active targeted transport platform","volume":"30","author":"Zhang","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2024.102195_bib186","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ncrna.2022.01.001","article-title":"Exosomal RNAs in diagnosis and therapies","volume":"7","author":"Narang","year":"2022","journal-title":"Noncoding. RNA Res."},{"key":"10.1016\/j.omtn.2024.102195_bib187","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020598","article-title":"Exosome-based carrier for RNA delivery: progress and challenges","volume":"15","author":"Lu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib188","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/jcp.25766","article-title":"Exosomes: Nanoparticulate tools for RNA interference and drug delivery","volume":"232","author":"Shahabipour","year":"2017","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.omtn.2024.102195_bib189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajps.2017.07.008","article-title":"Exosome-based small RNA delivery: Progress and prospects","volume":"13","author":"Lu","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib190","article-title":"Arrowtail RNA for ligand display on ginger exosome-like nanovesicles to systemic deliver siRNA for cancer suppression","volume":"8","author":"Li","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2024.102195_bib191","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1021\/acs.nanolett.8b02689","article-title":"In\u00a0vitro and in\u00a0vivo RNA inhibition by CD9-HuR functionalized exosomes encapsulated with miRNA or CRISPR\/dCas9","volume":"19","author":"Li","year":"2019","journal-title":"Nano Lett."},{"key":"10.1016\/j.omtn.2024.102195_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101266","article-title":"Exosome-mediated mRNA delivery in\u00a0vivo is safe and can be used to induce SARS-CoV-2 immunity","volume":"297","author":"Tsai","year":"2021","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2024.102195_bib193","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11051-022-05396-5","article-title":"Polymeric nanoparticles as therapeutic agents against coronavirus disease","volume":"24","author":"Charelli","year":"2022","journal-title":"J.\u00a0Nanopart. Res."},{"key":"10.1016\/j.omtn.2024.102195_bib194","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11060280","article-title":"Recent progress in the development of poly(lactic-co-glycolic acid)-based nanostructures for cancer imaging and therapy","volume":"11","author":"Kim","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib195","doi-asserted-by":"crossref","first-page":"35835","DOI":"10.1021\/acsami.0c08268","article-title":"Surface-functionalized PEGylated nanoparticles deliver messenger RNA to pulmonary immune cells","volume":"12","author":"Ke","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omtn.2024.102195_bib196","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s13346-020-00725-4","article-title":"Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates","volume":"10","author":"Tan","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.omtn.2024.102195_bib197","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1021\/mp3004176","article-title":"Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties","volume":"9","author":"Sunshine","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.omtn.2024.102195_bib198","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biomaterials.2019.04.020","article-title":"Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in\u00a0vitro and in\u00a0vivo","volume":"209","author":"Kozielski","year":"2019","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2024.102195_bib199","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/adma.201204346","article-title":"Degradable terpolymers with alkyl side chains demonstrate enhanced gene delivery potency and nanoparticle stability","volume":"25","author":"Eltoukhy","year":"2013","journal-title":"Adv. Mater."},{"key":"10.1016\/j.omtn.2024.102195_bib200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fphar.2017.00261","article-title":"Impact of dendrimers on solubility of hydrophobic drug molecules","volume":"8","author":"Choudhary","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib201","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jconrel.2007.06.012","article-title":"Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy","volume":"122","author":"Lai","year":"2007","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtn.2024.102195_bib202","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.colsurfb.2017.06.025","article-title":"Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers","volume":"157","author":"Luong","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.omtn.2024.102195_bib203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.nano.2017.11.010","article-title":"Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment","volume":"14","author":"Amreddy","year":"2018","journal-title":"Nanomedicine."},{"key":"10.1016\/j.omtn.2024.102195_bib204","doi-asserted-by":"crossref","DOI":"10.1038\/srep29436","article-title":"Self-assembly of amphiphilic dendrimers: The role of generation and alkyl chain length in siRNA interaction","volume":"6","author":"M\u00e1rquez-Miranda","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2024.102195_bib205","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1021\/accountsmr.1c00272","article-title":"Amphiphilic dendrimer vectors for RNA delivery: state-of-the-art and future perspective","volume":"3","author":"Chen","year":"2022","journal-title":"Acc. Mater. Res."},{"key":"10.1016\/j.omtn.2024.102195_bib206","first-page":"2717","article-title":"Synthesis, characterization and applications of poly-aliphatic amine dendrimers and dendrons","volume":"17","author":"Gillani","year":"2020","journal-title":"J.\u00a0Iran. Chem. Soc."},{"key":"10.1016\/j.omtn.2024.102195_bib207","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.biomaterials.2014.03.040","article-title":"Fluorinated poly(propylenimine) dendrimers as gene vectors","volume":"35","author":"Liu","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.omtn.2024.102195_bib208","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25173982","article-title":"Applications and limitations of dendrimers in biomedicine","volume":"25","author":"Chis","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2024.102195_bib209","article-title":"Safety challenges and application strategies for the use of dendrimers in medicine","volume":"14","author":"Li","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib210","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.3390\/s8116791","article-title":"An electrochemical DNA biosensor developed on a nanocomposite platform of gold and poly(propyleneimine) dendrimer","volume":"8","author":"Arotiba","year":"2008","journal-title":"Sensors"},{"key":"10.1016\/j.omtn.2024.102195_bib211","series-title":"Functional Polymers","author":"Mohammad","year":"2019"},{"key":"10.1016\/j.omtn.2024.102195_bib212","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/nat.2011.0293","article-title":"Polymers in small-interfering RNA delivery","volume":"21","author":"Singha","year":"2011","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib213","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/adhm.201300601","article-title":"Peptide dendrimer-doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy","volume":"3","author":"Zhang","year":"2014","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.omtn.2024.102195_bib214","first-page":"1800","article-title":"Cell-penetrating peptides as vehicles for delivery of therapeutic nucleic acids. mechanisms and application in medicine","volume":"88","author":"Timotievich","year":"2023","journal-title":"Biochemistry."},{"key":"10.1016\/j.omtn.2024.102195_bib215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/mt.2008.215","article-title":"A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells","volume":"17","author":"Crombez","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib216","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300236","article-title":"Cell penetrating peptides: classification, mechanisms, methods of study, and applications","volume":"18","author":"Gori","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.omtn.2024.102195_bib217","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.2147\/DDDT.S330059","article-title":"Cell-penetrating peptide-modified graphene oxide nanoparticles loaded with rictor siRNA for the treatment of triple-negative breast cancer","volume":"15","author":"Yang","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib218","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/10717544.2019.1667453","article-title":"Delivery of antisense oligonucleotide using polyethylenimine-based lipid nanoparticle modified with cell penetrating peptide","volume":"26","author":"Yang","year":"2019","journal-title":"Drug Deliv."},{"key":"10.1016\/j.omtn.2024.102195_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120398","article-title":"Endosomal escape cell-penetrating peptides significantly enhance pharmacological effectiveness and CNS activity of systemically administered antisense oligonucleotides","volume":"599","author":"Dastpeyman","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.omtn.2024.102195_bib220","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030118","article-title":"Mesoporous silica nanoparticles: A comprehensive review on synthesis and recent advances","volume":"10","author":"Narayan","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib221","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s11671-017-1853-y","article-title":"Size, stability, and porosity of mesoporous nanoparticles characterized with light scattering","volume":"12","author":"Kaasalainen","year":"2017","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.omtn.2024.102195_bib222","series-title":"New Developments in Nanosensors for Pharmaceutical Analysis","first-page":"29","article-title":"Nanomaterials for drug delivery systems","author":"Esim","year":"2019"},{"key":"10.1016\/j.omtn.2024.102195_bib223","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/molecules23010047","article-title":"Mesoporous silica nanoparticles for drug delivery: current insights","volume":"23","author":"Vallet-Reg\u00ed","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.omtn.2024.102195_bib224","article-title":"Development of dual-pore coexisting branched silica nanoparticles for efficient gene-chemo cancer therapy","volume":"14","author":"Lee","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.omtn.2024.102195_bib225","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11302-012-9338-z","article-title":"Modulation of G protein-coupled adenosine receptors by strategically functionalized agonists and antagonists immobilized on gold nanoparticles","volume":"9","author":"Jayasekara","year":"2013","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.omtn.2024.102195_bib226","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1038\/s41467-021-23250-5","article-title":"Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs","volume":"12","author":"Xue","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2024.102195_bib227","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.cclet.2017.07.012","article-title":"Advances in quantum dot-mediated siRNA delivery","volume":"28","author":"He","year":"2017","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.omtn.2024.102195_bib228","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.7150\/thno.87316","article-title":"Targeting materials and strategies for RNA delivery","volume":"13","author":"Lin","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.omtn.2024.102195_bib229","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1126\/sciadv.ade1444","article-title":"Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer","volume":"9","author":"Melamed","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2024.102195_bib230","series-title":"Challenges in Delivery of Therapeutic Genomics and Proteomics","first-page":"325","article-title":"Antisense oligonucleotides and RNA interference","author":"Kher","year":"2011"},{"key":"10.1016\/j.omtn.2024.102195_bib231","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010746","article-title":"Clinical pharmacokinetics of approved RNA therapeutics","volume":"24","author":"Jo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib232","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122678","article-title":"Intradermal delivery of naked mRNA vaccines via iontophoresis","volume":"15","author":"Hasan","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2024.102195_bib233","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s11427-022-2314-8","article-title":"Local administration of liposomal-based Plekhf1 gene therapy attenuates pulmonary fibrosis by modulating macrophage polarization","volume":"66","author":"Yan","year":"2023","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib234","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7831\/ras.7.10","article-title":"Systemic delivery of small interfering RNA therapeutics: obstacles and advances","volume":"7","author":"Chandela","year":"2019","journal-title":"Rev. Agri. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib235","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd4685","article-title":"Clinical experiences with systemically administered siRNA-based therapeutics in cancer","volume":"14","author":"Zuckerman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtn.2024.102195_bib236","series-title":"Biomedical Sciences, vol. Master of Science","article-title":"A study of cobalt (III) oxide nanoparticle delivery of siRNA molecules directed against signaling intermediates of the P2Y2 receptor","author":"Stroud","year":"2022"},{"key":"10.1016\/j.omtn.2024.102195_bib237","doi-asserted-by":"crossref","first-page":"L894","DOI":"10.1152\/ajplung.00426.2018","article-title":"Regulation of ovarian cancer G protein-coupled receptor-1 expression and signaling","volume":"316","author":"Nayak","year":"2019","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.omtn.2024.102195_bib238","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2020.03.004","article-title":"The proton-sensing receptor ovarian cancer G-protein coupled receptor 1 (OGR1) in airway physiology and disease","volume":"51","author":"Nayak","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib239","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002449","article-title":"An siRNA screen in pancreatic beta cells reveals a role for Gpr27 in insulin production","volume":"8","author":"Ku","year":"2012","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2024.102195_bib240","article-title":"Small activating RNA modulation of the G protein-coupled receptor for cancer treatment","volume":"9","author":"Xiong","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib241","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.2174\/0929867324666170830111531","article-title":"Targeting CXCL12\/CXCR4 axis in tumor immunotherapy","volume":"26","author":"Zhou","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.omtn.2024.102195_bib242","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s10120-019-01011-0","article-title":"LncRNA COL1A1-014 is involved in the progression of gastric cancer via regulating CXCL12-CXCR4 axis","volume":"23","author":"Dong","year":"2020","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.omtn.2024.102195_bib243","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.semcancer.2022.03.002","article-title":"Integration of chemokine signaling with non-coding RNAs in tumor microenvironment and heterogeneity in different cancers","volume":"86","author":"Arora","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib244","first-page":"10","article-title":"LncNORAD interference inhibits tumor growth and lung cancer cell proliferation, invasion and migration by down-regulating CXCR4 to suppress RhoA\/ROCK signaling pathway","volume":"24","author":"Wu","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.omtn.2024.102195_bib245","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107355","article-title":"miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4","volume":"92","author":"Azar","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.omtn.2024.102195_bib246","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.2147\/OTT.S235970","article-title":"Long non-coding RNA FEZF1-AS1 modulates CXCR4 to promote cell proliferation, warburg effect and suppress cell apoptosis in osteosarcoma by sponging miR-144","volume":"13","author":"Liu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib247","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omtn.2024.102195_bib248","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/cb400704n","article-title":"Prometastatic GPCR CD97 is a direct target of tumor suppressor microRNA-126","volume":"9","author":"Lu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib249","doi-asserted-by":"crossref","first-page":"540","DOI":"10.3389\/fcell.2020.00540","article-title":"MicroRNA-138-5p suppresses non-small cell lung cancer cells by targeting PD-L1\/PD-1 to regulate tumor microenvironment","volume":"8","author":"Song","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib250","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1517\/14712598.1.6.979","article-title":"RASONs: a novel antisense oligonucleotide therapeutic approach for asthma","volume":"1","author":"Sandrasagra","year":"2001","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omtn.2024.102195_bib251","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nchembio.2126","article-title":"Conformationally selective RNA aptamers allosterically modulate the beta2-adrenoceptor","volume":"12","author":"Kahsai","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.omtn.2024.102195_bib252","series-title":"Highlights of Prescribing Information - Olinvyk (oliceridine)","year":"2021"},{"key":"10.1016\/j.omtn.2024.102195_bib253","first-page":"18","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Alexander","year":"2020","journal-title":"Sci. Signal."},{"key":"10.1016\/j.omtn.2024.102195_bib254","article-title":"Nanoparticle drug delivery systems for synergistic delivery of tumor therapy","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124000829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124000829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T16:51:08Z","timestamp":1718124668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253124000829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":253,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2162253124000829"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102195","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"102195"}}